نتائج البحث

Estimating the clinical and budgetary impact of using angiotensin receptor neprilysin inhibitor as first line therapy in patients with HFrEF

• Authors : Bergh, N; Lindmark, K; Lissdaniels, J

Subjects: Medicin och hälsovetenskap

• Source: ESC heart failure. 11(2):1153-1162

تفاصيل العنوان

Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART2)

• Source: A Multicenter, NI, Retrospective, Observational Study Evaluating Real-World Treatment Outcomes in Japanese Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Avelumab Plus Axitinib as

تفاصيل العنوان

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

• Source: A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With

تفاصيل العنوان

Effectiveness of Methotrexate Versus Prednisone As First-line Therapy for Pulmonary Sarcoidosis (PREDMETH)

• Authors : St. Antonius Hospital; Longfonds; Marlies Wijsenbeek, Principal investigator

• Source: The PREDMETH Trial: Effectiveness of Methotrexate Versus Prednisone As First-line Therapy for Pulmonary

تفاصيل العنوان

Mosunetuzumab with Lenalidomide Augmentation As First-line Therapy for Follicular and Marginal Zone Lymphoma

• Authors : Genentech, Inc.

• Source: BrUOG 401: a Phase 2 Study of Mosunetuzumab with Lenalidomide Augmentation As First-line Therapy for

تفاصيل العنوان

Safety and Efficacy of EIK1001-006 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

• Authors : Merck Sharp & Dohme LLC

• Source: A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as

تفاصيل العنوان

Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy

• Authors : Incyte Corporation

• Source: Phase II Randomized Study of Ruxolitinib vs Prednisone as First-Line Therapy for Chronic Graft vs Host

تفاصيل العنوان

Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC

• Authors : Amarex Clinical Research

• Source: A Phase 2 Randomized Open-Label Controlled Study to Evaluate the Efficacy and Safety of Ampligen in Combination With Standard of Care Versus SOC Alone Following

تفاصيل العنوان

Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation

• Source: A Phase 1b/2, Safety Lead-in and Dose-Expansion, Open Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Activity of Ivosidenib in Combination With Durvalumab and

تفاصيل العنوان

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

• Authors : NRG Oncology

• Source: A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab (NSC #704865) Compared With Oxaliplatin and Capecitabine +/- Bevacizumab as

تفاصيل العنوان